3,4-Diaminopyridine 99% high purity certified Professional Producer Greenbo
54-96-6
Pharmaceutical Grade
99%
Shanghai
Greenbo
25K Drum
2022-07-31
Active Pharm Ingredients,Chemical Catalyst,Pharmaceutical Intermediates,Flavors and Fragrances,Agrochemicals,Chemical Pesticides
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceAmifampridine is a drug, predominantly in the treatment of a number of rare muscle diseases.Target: OthersAmifampridine is a drug, predominantly in the treatment of a number of rare muscle diseases. Amifampridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca2+ channels can then be open for a longer time and allow greater acetylcholine release to stimulate muscle at the end plate. A 2005 systematic review from the Cochrane
Amifampridine is an aminopyridine.|Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations. It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscular disorders, including Lambert–Eaton myasthenic syndrome (LEMS), has been investigated in the 1980s. Amifampridine phosphate is a more stable salt that serves as an active ingredient of EMA-approved Firdapse, which was previously marketed as Zenas. It is currently used as the first-line symptomatic treatment for LEMS in adult patients and is ideally given as oral tablets in divided doses, three or four times a day. Firdapse (amifampridine) was formally approved by the US FDA for the treatment of adults with LEMS as recently as November of 2018. LEMS is a rare auto-immune disorder of the neuromuscular junction that is characterized by proximal muscle weakness, depressed tendon reflexes, and posttetanic potentiation in addition to autonomic dysfunction. About 50-60% of the patients develop more rapidly progressive LEMS and small cell lung cancer, which influences the prognosis. Patients with LEMS develop serum antibodies against presynaptic P/Q-type voltage-gated calcium channels, leading to decreased presynaptic calcium levels and reduced quantal release of acetylcholine, which is mainly responsible for causing symptoms of LEMS. Reduced acetylcholine release at the neuromuscular junction leads to decreased frequency of miniature endplate potentials of normal amplitude, and insufficient acetylcholine levels for the activation of postsynaptic muscle fibers following a single nerve impulse. This leads to the reduction of the compound muscle action potential (CMAP). Treatment for LEMS include immunotherapy such as conventional immunosuppression or intravenous immunoglobulins, however such treatments are recommended in patients in whom symptomatic treatment would not suffice. Amifampridine is the nonimmune treatment options for LEMS. In phase III clinical trials of adult patients with LEMS, treatment of amifampridine significantly improved symptoms of LEMS compared to placebo with good tolerance. It was demonstrated in clinical studies involving healthy volunteers that the pharmacokinetics and systemic exposure to amifampridine is affected by the genetic differences in N-acetyl-transferase (NAT) enzymes (acetylator phenotype) and NAT2 genotype, which is subject to genetic variation. Slow acetylators were at higher risk for experiencing drug-associated adverse reactions, such as paresthesias, nausea, and headache.|Amifampridine is a Potassium Channel Blocker. The mechanism of action of amifampridine is as a Potassium Channel Antagonist.|Amifampridine is an orally available potassium channel blocker that increases acetylcholine in synaptic clefts of peripheral nerve endings and is used to treat the Lambert-Eaton myasthenic syndrome. Amifampridine is associated with a low rate of transient serum enzyme elevations during therapy but has not been linked with instances of clinically apparent acute liver injury.|Amifampridine is an organic compound derived from pyridine with potassium channel inhibition activity. Amifampridine inhibits potassium channel efflux, increasing the duration of the action potential, which results in an increase in the duration of calcium channel opening and enhanced acetylcholine (ACh) release. Increased ACh availability at the motor end plate allows muscles to contract.|4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.Basic Info-
Product Name:
3,4-Diaminopyridine
Other Name:3,4-Pyridinediamine;Pyridine,3,4-diamino-;3,4-Diaminopyridine;4,5-Diaminopyridine;NSC 521760;Amifampridine;Pyridine-4,5-diamine;DAP;3,4-DAP;Ruzurgi
CAS No.:54-96-6
Molecular Formula:C5H7N3
InChIKeys:InChIKey=OYTKINVCDFNREN-UHFFFAOYSA-N
Molecular Weight:109.13
Exact Mass:109.13
BRN:110232
EC Number:200-220-9
UNII:RU4S6E2G0J
NSC Number:521760
DSSTox ID:DTXSID6046715
NCI Thesaurus Code:C82687
ATC Code:N07XX05|N - Nervous system
HScode:29333999
Categories:
Characteristics-
PSA:
64.9
XLogP3:-0.5
Appearance:Brownish to brown-gray Crystalline Powder
Density:1.3±0.1 g/cm3
Melting Point:220 °C
Boiling Point:369.3°C at 760 mmHg
Flash Point:240 °C
Refractive Index:1.676
Water Solubility:H2O: 24 g/L (20 ºC)
Storage Conditions:Store below +30°C.
Toxicity:LD50 orally in Rabbit: 47 mg/kg LD50 dermal Rabbit > 200 mg/kg
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 2, Oral
Acute toxicity - Category 3, Dermal
Skin irritation, Category 2
Eye irritation, Category 2
Acute toxicity - Category 2, Inhalation
Specific target organ toxicity â single exposure, Category 3
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H300 Fatal if swallowed
H311 Toxic in contact with skin
H315 Causes skin irritation
H319 Causes serious eye irritation
H330 Fatal if inhaled
H335 May cause respiratory irritation
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P271 Use only outdoors or in a well-ventilated area.
P284 [In case of inadequate ventilation] wear respiratory protection.
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
Response P301+P316 IF SWALLOWED: Get emergency medical help immediately.
P321 Specific treatment (see ... on this label).
P330 Rinse mouth.
P302+P352 IF ON SKIN: Wash with plenty of water/...
P316 Get emergency medical help immediately.
P361+P364 Take off immediately all contaminated clothing and wash it before reuse.
P332+P317 If skin irritation occurs: Get medical help.
P362+P364 Take off contaminated clothing and wash it before reuse.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P320 Specific treatment is urgent (see ... on this label).
P319 Get medical help if you feel unwell.
Storage P405 Store locked up.
P403+P233 Store in a well-ventilated place. Keep container tightly closed.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Active Pharm Ingredients,Chemical Catalyst,Pharmaceutical Intermediates,Flavors and Fragrances,Agrochemicals,Chemical Pesticides
-
Location:
Zone K,Zwei Tianyuan Dushi Est,New Industial Park,High-tech Zone, Xian City,Shaanxi
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
15
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2017
-
Certifications:
international trade license,FSSC2000
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
